NCT00796484View on ClinicalTrials.gov

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Cancer
Interventions
DRUG

XL888

Administered orally

Trial Locations (2)

19104

Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY